Context: Subclinical hypothyroidism has been associated with increased risk of coronary heart disease (CHD), particularly with thyrotropin levels of 10.0 mIU/L or greater. The measurement of thyroid antibodies helps predict the progression to overt hypothyroidism, but it is unclear whether thyroid autoimmunity independently affects CHD risk.
T he prevalence of subclinical hypothyroidism increases with age and is highest among older women (1, 2) . Controversy persists as to whether population-wide screening and treatment of subclinical thyroid dysfunction are warranted (1, 3) . Current evidence about the risks of subclinical hypothyroidism remains limited (1, 3) , and randomized clinical trials on relevant clinical outcomes have not been performed to date (1, 4) . Our recent individual participant data analysis found that subclinical hypothyroidism [defined as elevated TSH level (4.5-19.9 mIU/L) and normal free T 4 level] was associated with coronary heart disease (CHD) mortality and CHD events, with a stronger association for those with TSH of 10.0 mIU/L or greater (5) .
The presence of thyroid antibodies predicts the risk of progression from subclinical to overt hypothyroidism (6 -9) . Among 1877 subjects (56% women), both raised TSH level, and the presence of thyroid antibodies at baseline were associated with development of hypothyroidism over a 20-year follow-up (6) . Among 92 women (mean age 50.7 y) with subclinical hypothyroidism followed up for 9 years, the incidence of overt hypothyroidism increased from 23.2% to 58.5% with the presence of antimicrosomal antibodies (P ϭ .03) (10) . Although recommendations in guidelines about measuring thyroid antibodies to better identify patients who should receive levothyroxine replacement differ (1, 3) , physicians include thyroid antibody status in their decision of whether to treat subclinical hypothyroidism (11) .
Because the presence of thyroid antibodies is associated with more progression from subclinical to overt hypothyroidism (6 -10) and overt hypothyroidism with increased cardiovascular risk (12) , one may infer that subclinical hypothyroidism with positive thyroid antibodies might be also associated with increased risks of CHD mortality or events, although this has not been studied in appropriately sized studies with clinical outcomes. Indeed, thyroid antibodies have been associated with increased markers of endothelial dysfunction that may lead to atherosclerosis (13) . However, it is unknown whether the presence of thyroid antibodies in subclinical hypothyroidism predicts patient-relevant cardiovascular outcomes, such as CHD events. Only a few previous studies have reported clinical cardiovascular outcomes, with conflicting data (14 -18) . The studies also had limited power with a relatively low number of events and did not provide subgroup analyses (eg, by TSH levels or age).
We therefore aimed to compare the risks of CHD mortality and events associated with subclinical hypothyroidism by thyroid antibody status using individual participant data from our Thyroid Studies Collaboration (5, 19, 20) .
Materials and Methods

Data sources and study selection
As previously described (5, 19, 20) , we identified prospective cohort studies and collected their individual participant data based on a systematic literature review of MEDLINE and EMBASE databases from 1950 to June 30, 2011, with no language restriction, and screened bibliographies of selected articles (Supplemental Appendix Methods). We included studies with a priori criteria: full-text published longitudinal cohort studies, reporting baseline levels of thyroid function (TSH and T 4 ) and antibodies, with a control euthyroid group and prospective follow-up of cause-specific mortality and CHD outcomes. We excluded studies in which only participants taking thyroid medications (antithyroid drugs, levothyroxin, or amiodarone) or participants with only overt hypothyroidism (high TSH and low T 4 levels) were included.
Data extraction and quality assessment
Investigators from each original study were invited to join the Thyroid Studies Collaboration and to share individual participant data, as previously described (5, 19, 20) . We collected demographic data, TSH, free T 4 , or total T 4 in one study (14) , thyroid antibodies, baseline cardiovascular risk factors (ie, blood pressure, cigarette smoking status, total cholesterol level, diabetes mellitus), body mass index (BMI) (weight in kilograms divided by squared height in meters), cardiovascular and thyroid medication use, and outcome data on CHD events and mortality.
We assessed study quality using previous criteria (21) after collecting additional information from study authors: methods of outcome adjudication and ascertainment, accounting for confounders, and completeness of follow-up.
Data synthesis and analysis
Similar to our previous analyses (5, 19, 20) , we used a uniform TSH cutoff level, based on an expert consensus meeting of our Thyroid Studies Collaboration (International Thyroid Conference, Paris, 2010), expert reviews (1), and previous large cohorts (15, 22) . Euthyroidism was defined as TSH 0.45-4.49 mIU/L and subclinical hypothyroidism as TSH 4.5-19.9 mIU/L and normal T 4 level. Similar to our previous analysis on subclinical hypothyroidism (5), we used a study-specific TSH reference range of 6.0 -21.5 mIU/L for participants in the Whickham Survey (14) because of the first-generation TSH RIA in this study that gives higher measured TSH values than current assays (23) . For participants in the Study of Health in Pomerania (24) , an iodine fortification program was started a few years before inclusion; thus, a TSH reference range of 0.25-2.12 mIU/L was used as suggested for iodine-deficient areas (25); we further performed a sensitivity analysis excluding this study. Without this study-specific TSH range, a large group of participants would have been considered subclinically hyperthyroid (n ϭ 706, 18.4%) and very few subclinically hypothyroid (n ϭ 13, 0.4%).
For T 4 level, we used study-and method-specific cutoff values (Supplemental Appendix (5, 19, 20) , we assumed that these participants had subclinical hypothyroidism because most adults with this degree of TSH elevation have subclinical rather than overt hypothyroidism (2) . We performed a sensitivity analysis excluding those participants with missing T 4 values. Thyroid antibodies were measured by different assays in the original cohorts, and we used assay-specific cutoff values (Supplemental Appendix Table 1 ). In two older cohorts, levels of antimicrosomal antibodies (22) and thyroid anticytoplasmic antibodies (14) were available instead of the more precise thyroid peroxidase antibodies (TPOAbs) in the four other cohorts (26) . Therefore, we conducted a sensitivity analysis excluding the two studies relying on older assays for thyroid antibodies. We also performed sensitivity analyses excluding thyroid medication users at baseline and then at baseline and during follow-up as well as analyses limited to participants with a TSH of 10.0 mIU/L or greater.
Outcomes were CHD events and CHD mortality. Similar to our previous analyses (5, 19) , we used more homogenous definitions to limit the outcome heterogeneity observed in a previous study-level analysis (21) . Similar to the Framingham risk score (27) , we limited cardiovascular mortality to CHD mortality or sudden death (Supplemental Appendix Table 1 ). We defined CHD events as nonfatal myocardial infarction (MI) or CHD death [equivalent to hard events in the Framingham risk score (27) ] or hospitalization for angina or coronary revascularization (22) . Data on heart failure (HF) outcome were available from one study (22) with thyroid antibodies. Incident HF events were assessed in participants free of HF at baseline and adjudicated every 6 months based on an interview, a review of medical records, and other support documents without the knowledge of thyroid status (28) .
Statistical analyses
Similar to our previous studies (5, 19, 20) , we analyzed the association between subclinical hypothyroidism with and without antibodies and each outcome using separate Cox proportional hazard models of individual participant data from each cohort (SAS version 9.2; SAS Institute Inc; Stata 12.1; StataCorp). Pooled estimates for each outcome were calculated with random-effects models based on the inverse variance model as recommended in two-stage individual participant data analyses (29, 30) . Results were summarized using forest plots (Review Manager version 5.1.7; Nordic Cochrane Centre). To assess heterogeneity across studies, we applied the I 2 statistic, which measures the inconsistency across studies attributable to heterogeneity instead of chance alone (31) . We analyzed the potential additional effect of TPOAbs to predict CHD outcomes in subclinical hypothyroidism by interaction tests: we compared pooled estimates of the risk of CHD outcomes for TPOAb-positive subclinical hypothyroidism vs euthyroidism and TPOAbnegative subclinical hypothyroidism vs euthyroidism using interaction tests.
Primary analyses were adjusted for age and sex [some traditional cardiovascular risk factors being potential mediators of CHD risk associated with subclinical hypothyroidism (12) ] and then further adjusted for cardiovascular risk factors (systolic blood pressure, smoking status, total cholesterol, diabetes), BMI, and lipid-lowering and antihypertensive medications. To explore the potential sources of heterogeneity, we performed predefined subgroup and sensitivity analyses as in our previous analyses (5, 19, 20) . We conducted stratified analyses by age, sex, and TSH category representing them as aggregate forest plots to summarize our findings. For some strata with participants but no event in subgroup analyses, we used penalized likelihood methods (32) to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). We checked the proportional hazard assumption using graphical methods and the Schoenfeld test (33) . To assess potential publication bias, we used age-and sex-adjusted funnel plots and the Egger test (34).
Results
We identified reports of six prospective cohorts meeting all inclusion criteria (Supplemental Appendix Figure 1 ) comprising 38 274 adults (median age 55 y, 62.9% women) recruited from the general population. A total of 36 583 were euthyroid and 1691 (4.4%) had subclinical hypothyroidism, of whom 775 (45.8%) had positive TPOAbs (Table 1) . Median follow-up was 12.2 years (interquartile range 11.2-13.1 y) for a total of 460 333 person-years, with a loss to follow-up rate less than 5% in all included studies.
During follow-up, 1436 participants in the whole sample died of CHD (Table 2) , and 3285 CHD events occurred among 33 394 participants from four cohorts having data on CHD events (14 -16, 22) (Table 3 ). In age-and sexadjusted analyses compared with euthyroid individuals, risks of CHD mortality were similar among those with TPOAb-positive subclinical hypothyroidism (HR 1.15, CI 0.87-1.53) and those with TPOAb-negative subclinical hypothyroidism (HR 1.26, CI 1.01-1.58, P for interaction ϭ .62) (Supplemental Appendix Figure 2 ). The risks of CHD events were also similar between subclinically hypothyroid TPOAb-positive and -negative individuals (HR 1.16, CI 0.87-1.56 vs HR 1.26, CI 1.02-1.56, respectively, P for interaction ϭ .65) (Supplemental Appendix Figure 2 ). Because heterogeneity was present across studies for CHD events (I 2 ϭ 49%) but not for CHD mortality (I 2 ϭ 0%), we subsequently assessed potential differences of risks according to subgroups. In stratified analyses, risks for CHD mortality and events increased with higher TSH levels, although with limited statistical evidence for a trend; power was more limited for these subgroup analyses compared with our previous analyses with 11 cohorts (5). However, at each TSH level, risks did not differ by TPOAb status (Figure 1 ). Risks differed slightly according to sex and age, although the interaction terms were not statistically significant (P for interaction Ն.39 for sex and P for interaction Ͼ.05 for age categories, Tables  2 and 3) .
Sensitivity analyses yielded comparable results ( Table  4 ). The exclusion of thyroid medication users at baseline or during follow-up yielded similar results including after further excluding two studies without data on thyroid medication during follow-up (16, 35) (data not shown). Risks were similar in multivariate models accounting for cardiovascular risk factors, lipid-lowering and antihypertensive medications, or BMI. Limiting analyses to studies with recent thyroid antibodies assays or to participants with TSH of 10.0 mIU/L or greater yielded overall higher risks of CHD mortality and events, but estimates did not differ according to TPOAb status (Supplemental Appendix Table 2 ).
When analyzing data from the four cohorts that measured TPOAbs in all participants, irrespective of TSH (n ϭ 9151) (14, 15, 24, 35) , the overall prevalence of TPOAb positivity was 6.5% (Supplemental Appendix Table 3 ). In age-and sex-adjusted analyses, CHD mortality risk was similar in the population with positive TPOAbs compared with those with negative TPOAbs (HR 1.09, CI 0.75-1.58) as well as for CHD events (HR 1.19, CI 0.93-1.53). Stratified analyses by gender yielded similar results (both P for interaction Ն.40). This post hoc analysis showed similar results to the main analyses of subclinical hypothyroidism according to TPOAb status, with lower power due to the number of participants.
One study had data on thyroid antibodies and incident HF events (22) . Among the 2985 older participants, 695 (27.5%) individuals in the euthyroid state and 116 (25.3%) with subclinical hypothyroidism developed HF. e For all cohorts, we used the maximal follow-up data that were available, which might differ from previous reports for some cohorts.
Age-and gender-adjusted analyses stratified by thyroid antibodies showed similar HF risks among those with thyroid antibody-positive subclinical hypothyroidism (HR 0.84, CI 0.61-1.14) and those with thyroid antibody-negative subclinical hypothyroidism (HR 1.01, CI 0.79 -1.28, P for interaction ϭ .37). Power was insufficient to assess HF risks stratified by both thyroid antibodies and TSH levels or other subgroups. (35) were not included in CHD events analysis because follow-up data were only available for death. b These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
c Strata from specific studies were excluded when there were fewer than five events or an empty comparison group. Abbreviation: SH, subclinical hypothyroidism. a Twenty-one participants were excluded from the analyses of CHD mortality because of missing cause of death.
b These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
c Strata from specific studies were excluded when there were fewer than five events or an empty comparison group. The proportional hazard assumption was consistent across studies (all P Ͼ .10). We found limited evidence of publication bias with visual assessment of age-and gender-adjusted funnel plots and the Egger test for CHD mortality (P ϭ .50) and CHD events (P ϭ .060).
Discussion
In this analysis of data from more than 38 000 individuals recruited in six prospective cohorts, risks of CHD mortality and CHD events associated with subclinical hypothyroidism did not differ according to TPOAb status. In stratified analyses, risks increased with higher TSH levels but did not differ by TPOAb status at each TSH level.
These results are consistent with most previous studies. In a recent analysis, LeGrys et al (17) found no association between the presence of TPOAbs in subclinical hypothyroidism and subsequent MI events among postmenopausal women. Similar results were also found for reports of single cohorts included in the Thyroid Studies Collaboration, such as the Whickham Survey (14) , the NordTrøndelag Health Study (HUNT) (16) , and the Busselton Health Study (15) . However, in the Rotterdam Study, the presence of positive TPOAbs in subclinical hypothyroidism was associated with prevalent MI compared with euthyroid women (18) , but there were not enough events for a prospective analysis of this association (16 first incident MIs over 4.6 y) (21) .
Because thyroid autoimmunity has been associated with a higher risk for progression from subclinical to overt hypothyroidism (6 -10), progression of atherosclerosis (18, 36) , and overt hypothyroidism with increased cardiovascular risk (12) , one may expect that TPOAb-positive subclinical hypothyroidism would also be associated with more CHD mortality or events. This was not confirmed in our analysis. A possible explanation is that physicians may rely on TPOAb status to decide whether to start levothyroxine treatment, as recommended by some current guidelines (3), and that such treatment may have reduced the risk of CHD. However, our sensitivity anal- 
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Collet et al Thyroid Antibodies and Coronary Heart Disease J Clin Endocrinol Metab, September 2014, 99(9):3353-3362 (37) , and adiposity is also associated with increased CHD risk (38) . However, adjusting for BMI (our best measure of adiposity) did not change the present results. To summarize, the presence of TPOAb may be a good marker of progression of subclinical to overt hypothyroidism, but a poor marker for stratification of who will develop cardiovascular complications (3). Our analyses show that any risk of CHD is mediated through thyroid dysfunction (5), without an independent contribution from autoimmune dysfunction. This adds to the current knowledge about the pathophysiology of thyroid-related CHD and has clinical implications because thyroid dysfunction is a treatable risk factor and thyroid autoimmunity is not. Our study is the largest to investigate the association between TPOAb status and cardiovascular risk in participants with subclinical hypothyroidism. The analysis of individual participant data from several studies allowed us to analyze subgroup data that have less potential bias than study-level meta-analyses. Study strengths are the inclusion of time-to-event analyses and the use of standardized definitions of predictors, outcomes, and adjustment for confounding factors (29) .
The study had the following limitations. Participants were mainly Caucasians, except for one cohort including Brazilians of Japanese descent (35) , so our results may not apply to other populations. Second, thyroid function tests were performed only at baseline, which is a limitation of most published cohort studies. The number of participants with subclinical hypothyroidism at baseline that normalized to euthyroid state over time or those who progressed to overt hypothyroidism is unknown, although previous studies showed a low proportion of progression over 20 years of follow-up (14) . Moreover, recent studies found similar results for risk of CHD using single or repeated TSH measurements among the elderly within the Cardiovascular Health Study (28) . In a recent study of the oldest old, there were no associations between baseline levels and a 13-year change in TSH, free T 4 levels, and TPOAb positivity and mortality (39) . Third, older thyroid antibodies assays were used in two included cohorts [antimicrosomal antibodies (22) and thyroid cytoplasmic antibodies (14) ], but sensitivity analyses excluding cohorts with older assays yielded similar results. Because thyroglobulin antibodies (TgAbs) were not available in the three largest cohorts, there was insufficient power to examine the risks associated with thyroglobulin antibodies. However, the lack of TgAbs in our analyses should not be a major limitation because most people (70%) who had positive TgAbs in National Health and Nutrition Examination Survey III also had positive TPOAbs (2). Moreover, both in the National Health and Nutrition Examination Survey III [cross-sectional (2)] and the Busselton Health Study [longitudinal analysis (40) ], a positive TgAb alone in the absence of positive TPOAb was not a predictor of thyroid disease. Fourth, during follow-up of individuals with subclinical hypothyroidism, 90 of the 294 participants with positive thyroid antibodies (30.6%) and 67 of the 378 participants with negative thyroid antibodies (17.7%) were treated with T 4 . However, sensitivity analyses excluding thyroid medication users yielded similar results.
Current guidelines for the management of subclinical hypothyroidism are conflicting about measuring TPOAbs to target treatment in patients with subclinical hypothyroidism (1, 3) . Although the presence of TPOAbs in subclinical hypothyroidism predicts the evolution to overt hypothyroidism, we found that it did not predict CHD outcomes associated with subclinical hypothyroidism, suggesting that biomarkers of thyroid autoimmunity do not add independent prognostic information on CHD outcomes. Thyroid antibodies may be useful for investigating the etiology of subclinical hypothyroidism and to predict the potential evolution to overt hypothyroidism. Because of the absence of prediction of TPOAb status on CHD risks in subclinical hypothyroidism, other biomarkers should be examined to identify patients at increased cardiovascular risk. Randomized clinical trials are needed to clarify whether the presence of thyroid antibodies to target treatment in patients predicts a larger benefit of levothyroxine treatment of subclinical hypothyroidism on clinical outcomes (4, 41) . None of the sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
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